|Biotech partner:||Glenmark (India)|
|Pharma Partner:||Sanofi-Aventis (France)|
|Type of agreement:||* R&D
* commercialization/ distribution
* marketing/ promotion
|Compound:||vanilloid receptor (TRPV3) antagonist molecules, including a first-in-class clinical compound, GRC 15300. The TRPV3 receptor is an ion channel protein that mediates and influences cell signaling, including the nerve cell signaling that generates some types of pain. Inhibitors of TRPV3 are predicted to be useful in the treatment of inflammation, various pain conditions, and other diseases and disorders.|
|Disease area:||chronic pain|
|Development phase:||GRC 15300 is currently in Phase I clinical development as a potential next-generation treatment for various pain conditions, including diabetic neuropathic pain and osteoarthritic pain.|
|Nature of the agreement:||Sanofi-Aventis and Glenmark Pharmaceuticals have entered into an agreement to grant Sanofi-Aventis a license for the development and commercialization of novel agents to treat chronic pain.
Those agents are vanilloid receptor (TRPV3) antagonist molecules, including a first-in-class clinical compound, GRC 15300.
Sanofi-aventis will have exclusive marketing rights for North America, European Union and Japan subject to Glenmark's right to co-promote the products in the USA and five Eastern European countries. Sanofi- aventis will also have co-marketing rights in 10 other countries including Brazil, Russia, and China, whereas Glenmark will retain exclusive rights in India and other countries of the rest of the world.
|Financial terms of the agreement:||Under the terms of the agreement, Glenmark will receive an upfront payment of US $ 20 million, as well as development, regulatory and commercial milestone payments. All such payments could reach a total of U.S. $ 325 million. In addition, Glenmark is eligible to receive tiered double-digit royalties on sales of products commercialized under the license.|